Surprising starts often turn out to be aberrations as we get deeper into the season, but several strong April performances have proven to have some staying power.
Paul Skenes is coming off his worst start since Opening Day and the Blue Jays are trying to get their bats going as they continue their series vs. the Pirates at 3 p.m. ET in Toronto.
With the Hall of Fame Military Classic Presented by New Era this weekend, Cooperstown also opened a pair of new exhibits with one featuring the flag Rick Monday rescued 50 years ago.
With the Red Sox giving away a bobblehead commemorating Roger Clemens’ pair of 20-K games, the Rocket threw out the first pitch … to his son Kody, in town playing for the Twins.
Follow the smart money. This report reveals stocks seeing strong insider buying-often a signal of confidence and potential upside. Discover where executives are investing their own capital and which companies could be positioned for moves the market hasn’t priced in yet.
Wall Street living legend Marc Chaikin has returned with his #1 Stock Pick for 2026. This is his highest conviction pick to survive an increasingly dangerous U.S. stock market. And if you’re thinking it’s NVDA, TSLA, or the Mag 7, you’re dead wrong. More Info ➔Rocket Lab Lands $90 Million US Space Force Deal
WASHINGTON (AP) — In the year since President Donald Trump promising to create a deep-sea mining industry from scratch, businesses have raised millions of dollars from investors, stock prices have soared and federal regulators have raced to fast-track a permitting process. More Info ➔SpaceX reveals plans for what could be the biggest-ever initial public offering
Trump, Gavin Newsom, Anthony Scaramucci, and Neil deGrasse Tyson were among the figures driving major political news. More Info ➔
Information, charts, or examples contained in this email are for illustration and educational purposes only and not for individualized investment management. This message contains commercial elements, such as advertising and partner offers for which we may receive affiliate compensation. We only send these offers to those who have opted into our newsletter.
If you wish to no longer receive these offers, click on the unsubscribe link at the bottom of this email. Past performance is not indicative of future results. For these reasons, we strongly suggest trading in a DEMO/Simulated account.
The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices, or procedures of any company or entity mentioned or recommended in this email and have not determined if the statements and opinions of the advertiser are accurate, correct, or truthful.
If you use, act upon, or make decisions in reliance on information contained in this email or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates, and agents without fault.
2967 Dundas St. W. #990, Toronto, ON M6P 1Z2 | Phone Number: 917.672.7040
Shares of Eli Lilly and Company (NYSE: LLY), the world’s most valuable pharmaceutical stock, started 2026 in a bad way. Near the end of April, LLY shares had fallen as much as 20%. However, the stock has rebounded mightily since then.
Lilly’s highly impressive earnings reportkicked off the rally, with shares surging nearly 10% in one day. Lilly has continued to trudge higher, now down only around 5% in 2026.
One event that recently helped Lilly’s stock move up was the latest results surrounding its oral GLP-1 medication Foundayo. While Foundayo is already approved by the Food and Drug Administration, the need to continue testing does not stop there. By generating more robust and a wider variety of data on the medication, Lilly can improve the chances of doctors prescribing it. Lilly’s latest results support this all-important goal.
If you still haven’t downloaded the free Simple Options Trading For Beginners guide…please take a few seconds and download it right now before your download link expires.
Foundayo’s 2-Pronged Attack: Needle Fear Patients and Maintenance Patients
The trial in question focuses on weight-loss maintenance—helping patients keep lost weight off after they stop taking high-dose GLP-1s. For Lilly, this is part of a two-pronged strategy to generate demand for Foundayo.
The first part is based on attracting completely new patients. Researchers estimate that up to 25% of U.S. adults have a fear of needles, preventing certain patients who want to lose weight from taking injectable GLP-1s. Through pill-based medications, Lilly can unlock demand from this patient group.
However, Lilly is falling behind Novo Nordisk A/S (NYSE: NVO) on oral uptake, as Novo received approval for its oral weight-loss drug several months earlier. Novo’s pill has also demonstrated efficacy that moderately surpasses Foundayo. Novo notes an average weight loss of 14% after 64 weeks among patients taking the Wegovy pill. This compares to an average weight loss of 12.4% after 72 weeks for Foundayo.
According to BMO Capital Markets, “While Foundayo scripts have been trending upward since launch in April, scripts have lagged vs. those of the Wegovy Pill and Street expectations.”
However, Lilly may be able to better differentiate itself in the second prong of its strategy: weight loss maintenance. Injectables are more efficacious than either pill, with Lilly touting an average weight loss of 20.2% at 72 weeks for patients using Zepbound. Thus, after losing a lot of weight on injectables, patients can transition to pills in order to keep lost weight off.
With this, Lilly can drive recurring sales of Foundayo as patients make the switch. Its latest Foundayo results provided encouraging data on this front.
Foundayo: Weight Loss Maintenance Improves Dramatically Versus Going Cold Turkey
In its ATTAIN-MAINTAIN trial, Lilly looked at patients who had lost significant weight through taking Zepbound. Throughout the Zepbound period, patients lost an average of 55 lbs. Patients then transitioned onto Foundayo for 52 weeks, gaining back 11 lbs. So, when using Foundayo as a maintenance treatment, patients regained only 20% of their original weight loss.
This is actually a strong showing, as patients who get off GLP-1s completely regain much more weight. A recent analysis of 48 studies found that after one year of getting off GLP-1s, patients regained 60% of their original weight loss. Thus, the percentage of weight loss kept in Lilly’s study is three times higher than that of those who got off GLP-1s completely.
Lilly also performed the same test with patients who originally lost 41 lbs by taking injectable Wegovy. After switching to Foundayo for 52 weeks, these patients regained just 2 lbs—another very strong result. In the end, Zepbound to Foundayo patients lost 17.2% of their weight, and Wegovy to Foundayo patients lost 15.5% of their weight on average.
Clearly, these results provide evidence that transitioning to Foundayo after taking injectables can be an effective pathway for keeping lost weight off. Notably, on the day of this data release, Lilly’s shares rose by 2.4%.
There is also reason to believe that Foundayo will have greater appeal as a weight-loss maintenance treatment than the Wegovy pill. This is because it comes with no dietary restrictions. Meanwhile, doctors advise Wegovy pill patients not to eat or drink for 30 minutes after taking the medication.
Ultimately, the convenience factor of pills is a key reason why people would want to switch from injectables. With no dietary restrictions, Lilly has an advantage here. However, it will be interesting to see if Novo conducts a similar maintenance study that could shift the playing field in this vertical.
When the SpaceX IPO launches, most retail investors will be locked out. The banks, funds, and insiders get in early – while everyone else waits on the sidelines.
But one small infrastructure supplier – a critical piece Musk can’t scale the Colossus network without – is still trading well under institutional radar. A new briefing reveals the name and ticker at no cost.Get the SpaceX infrastructure stock name and ticker here
Analysts Forecast Substantial Upside in Lilly After Recent Rebound
Overall, targeting the weight-loss maintenance market is one of many levers Eli Lilly can pull to continue growing its GLP-1 business. Notably, even with Lilly only down less than 10% from its all-time high, Wall Street analysts continue to forecast substantial gains ahead. The MarketBeat consensus price target on the stock sits near $1,218, implying upside of just over 20%.
Catholic “AI for good.” Instant answers and guidance to any question or problem. Try free for 7 days.
A Night Prayer
Jesus Christ, my God, I adore You and thank You for all the graces You have given me this day. I offer You my sleep and all the moments of this night. I place myself and all my loved ones, wherever they may be, in Your sacred side and under the mantle of Our Blessed Mother. Let Your holy angels stand watch and keep us in peace. Amen.
Quote of the Day
“Since we offend our sweet Jesus, every day, in thought, word, deed and the omission of good works, we should pray every day, and every hour of the day, and weep for our offenses against so kind and loving a Father, Master and Spouse.” -St. Rita
Today’s Meditation
“The contemplative life is an intimate affair; it is a loving conversation of man with God. but in order that God may speak to the soul and the soul speak with God, it is necessary that there be silence. Neither God nor our heart will be silent, but the earth and created things must be hushed, because everything worldly hinders the intimate conversation of our soul with God. This silence is not the silence of the desert nor of the tomb – a negative silence, the lack or suspension of life. It is like the apparel of a more interior life that one wears outside, because inside he is singing a love song. He does not speak with creatures, because he is speaking with God; he does not listen to the noise of earth, so that he might hear the harmonies of Heaven.” —Luis M. Martinez, p.37
Truthly is a Catholic AI app grounded in Scripture, Church teaching, and the Catholic intellectual tradition — designed to help you learn the faith, answer hard questions, and grow closer to God. Truthlycan answer any question with a Catholic lens.
The daily examination of conscience is an ancient Catholic practice. It’s very simple, and it’s designed to help us identify our sins and weaknesses so that we can improve and grow stronger in the spiritual life, while providing an excellent ongoing preparation for regular Confession. It consists of taking a few minutes at the end of the day to prayerfully review our actions in the light of God’s commandments, followed by the Act of Contrition.
Reflect on the victories and losses
Actively reflecting on the high and low points of the day can help you live more intentionally and bring a renewed sense of resolve into the following day.
Review your actions, words, and thoughts today. Did you actively guard yourself against temptation? Where did sin creep in?
In what moments did you practice virtue and moral courage?
Were you attuned to the Holy Spirit’s promptings today? Where did you feel His inspiration?
Ask Him for the graces necessary to follow His Will more purposefully tomorrow.
Act of Contrition
O my God, I am heartily sorry for having offended Thee, and I detest all my sins because of Thy just punishments, but most of all because they offend Thee, my God, Who art all good and deserving of all my love. I firmly resolve with the help of Thy grace to sin no more and to avoid the near occasions of sin. Amen.
Practice gratitude
It is God’s love that has brought you into existence and to this exact moment. Practice looking for His hand in your day.
Where did you feel His loving gaze upon you today?
What people or moments helped you see God in your life?
Thank God for all these moments!
Ask Him to help you recognize His blessings and providence tomorrow.
Renew your commitment to Christ
Remember: our Faith is founded upon a Person—Christ! Renew your personal love and devotion to Him.
Thank God for the gift of His Son Jesus and our call to be His disciples.
Tell the Lord of your desire to know Christ more personally.
If possible, set an intention for your day tomorrow. Ask Our Lord to guide you in this act.
Pray a Hail Mary, Our Father, or another beloved prayer.
Rest with God
My people will abide in a peaceful habitation, in secure dwellings, and in quiet resting places. — Isaiah 32:18
However, a convergence of pressures then hit the stock. This included artificial intelligence (AI) spending fears, legal losses, and the U.S.-Iran conflict that drove down the market as a whole. Near the end of March, Meta was down 20% on the year.
The stock has recovered considerably since that point, now down less than 10% in 2026. Meta’s return has hovered near this level since the end of April, after shares took a 8.6% hit following its Q1 2026 earnings report.
Meta is making moves to fight against the biggest headwind to its performance: increasing AI capital expenditure (CapEx) forecasts. The firm is undertaking some of its largest layoffs in recent memory, aimed at offsetting AI investment. However, markets don’t appear to be buying the story.
Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 – not chips, not funding, but power. Demand is growing 15% per year and the grid can’t keep up.
One small company makes the exact equipment these data centers need. They’re sitting on $1.5 billion in orders, their hardware is already inside Musk’s Colossus, and the stock still trades like a name nobody’s heard of. Analyst Dylan Jovine is releasing the ticker for free.See the stock positioned to solve AI’s biggest power crisis
Meta Initiates 10% Layoff—But for Much Different Reasons Than in the Past
In mid-May, reports emerged that Meta is laying off 8,000 employees. These job reductions account for approximately 10% of Meta’s total employee base.
The move marks the company’s most significant workforce shake-up since its “Year of Efficiency,” which took place between 2022 and 2023. This initiative cut 21,000 jobs.
However, there are significant differences between these recent cuts and the Year of Efficiency reductions.
Somewhat counterintuitively, Meta undertook one of its most aggressive hiring sprees ever from 2020 to 2022, during the height of the COVID pandemic.
By the end of 2022, Meta’s employee count had nearly doubled from the end of 2019, rising from around 45,000 to over 86,000. This came as COVID lockdowns pushed people to spend much more time on the internet and flock to e-commerce purchasing. This led to Meta’s sales growth soaring 37% year-over-year (YOY) in 2021.
The company loaded up on employees, believing that this was the beginning of a long-term tailwind for its business. However, as Meta admitted, this proved not to be the case, with sales dropping 1% YOY in 2022. In 2023, Meta dropped its employee count by 22% to around 67,000 in response.
Meta’s pasts cuts were a product of weaker-than-expected demand. That is not the case at all today.
Meta just posted its highest revenue growth in years at 33% YOY. Thus, demand is very strong, but it is being met with greater investments in technology rather than employees. In this sense, the move is much less a sign of weakness compared to mass layoffs in the past.
Layoffs Are Unlikely to Win Over Investors’ Hearts
Still, Meta shares haven’t really moved since recent layoffs began. This comes as investors likely don’t believe the cuts will have a huge impact on its financials.
Notably, analysts at Morgan Stanley have estimated that a 20% workforce reduction would generate annual savings of between $3 billion and $7 billion. At 10%, it’s fair to say that this forecast would move down to $1.5 billion to $3.5 billion.
Meta will also likely incur a significant charge to pay for severance packages. When it cut 10,000 employees in March 2023, its expected pre-tax severance charge and other personnel costs were $1 billion, which equates to $100,000 per employee. Holding this per-employee metric steady, the company may incur around $800 million in charges from the latest layoff, reducing the net near-term benefit.
Overall, Meta’s savings would be a drop in the bucket compared to the midpoint of its 2026 CapEx guidance of $135 billion. Furthermore, it’s unclear whether Meta will simply take whatever it saves from layoffs and allocate this to more AI investment, or if its CapEx guide will hold steady.
Either way, compared to its massive CapEx spending, the potential benefit of the layoffs is not much of a needle mover. This is likely one of the reasons shares have not benefited. Additionally, CEO Mark Zuckerberg told employees that he “does not expect more company-wide layoffs this year.”
This pushes back on past reports that the company would lay off 20% of its workforce in 2026. Investors may have viewed this as a disappointment, with actual cuts being much smaller.
SpaceX’s S-1 filing reveals $7.7 billion spent on AI infrastructure in a single quarter – not chips, not software, but power infrastructure. The filing shows $23.85 billion in servers and $14 billion in construction in progress, all dependent on one company’s hardware.
Without this supplier, Colossus doesn’t run and the $1.25 billion Anthropic pays monthly stops flowing. The stock is still trading like no one has read the filing – but analyst Dylan Jovine has, and he’s releasing the name at no cost.Read the S-1 breakdown and get the company name free
Growth Is the Key to Meta’s AI Journey
In aggregate, this data shows that Meta will not be able to justify its AI spending through layoffs alone. Rather, the company will need to grow its revenues, and eventually free cash flow, to do so.
In this context, the fact that Meta is also reassigning 7,000 employees to AI-related roles may be more impactful than the layoffs. After the layoffs, Meta’s employee count will fall to around 71,000. Thus, the firm will reallocate around 10% of its remaining workforce to AI-related roles. This increased focus on AI could allow the firm to better utilize its investments and drive growth.
Thank you for subscribing to DividendStocks.com’s daily newsletter for dividend and income investors that covers ex-dividend stocks, new dividend declarations, dividend stock ideas, and the latest market news.
If you need help with your newsletter, please don’t hesitate to email our South Dakota based support team at contact@marketbeat.com.
If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.
May 22, 2026 TODAY IN HISTORY Richard Nixon arrives in Moscow, the first visit by a U.S. president to the Soviet Union. 1972 TOP STORIES DNC Chair Faces Calls to Resign
We are still running special subscription deals in light of the ongoing war with Iran. Take this opportunity to become an Epoch Times subscriber—at the best rates possible—while they’re still available!
In a world where partisan and biased reporting has become commonplace, you can always count on The Epoch Times for a refreshing dose of factual, honest journalism without spin. When you don’t feel like reading the news, pick up a daily tip from us. From what to do with harmful byproducts in your coffee to how screen time can affect your different organs, our health coverage is deep and extensive. You will find your kind of healthy changes to make right away. Yet what makes you truly love The Epoch Times may be none of the above. It is our talks on art, culture, and history that move hearts. At nighttime or on an indolent Sunday afternoon, find yourself indulging in a fascinating read on stories you have been longing for: Pearl Harbor through the eyes of a navy salvage diver, the sparkly stories behind the stolen Louvre jewels, the every reason why you should throw a party… The list is endless. The inspiration is infinite.
Trump-backed candidate Ed Gallrein took incumbent Rep. Thomas Massie’s place in Kentucky. The primary race was just one of many, where Trump pushed campaigns of challengers on other key positions,…
Our Good Evening newsletter helps you catch up on the big stories of the day followed by lifestyle and uplifting content. Manage your email preferences here or unsubscribe from Good Evening here.
Insights, trends, and perspectives shaping today’s investment landscape.
RJ Hamster 